Abcam, ab320649, Anti-SFTPA1 + SFTPA2 antibody [EPR29098-6] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal Pulmonary surfactant-associated protein A1 antibody. Carrier free. Suitable for WB, IHC-P, mIHC and reacts with Transfected cell lysate - Human, Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR29098-6,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:IHC-P, WB, mIHCSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:The immunogen shares no sequence similarity with SFTPB, SFTPC or SFTPD. Based on the immunogen sequence, we do not expect this antibody to cross-react with SFTPB, SFTPC or SFTPD.

Product details:
ab320649 is the carrier-free version of
ab320648
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
SFTPA1 and SFTPA2 also known as surfactant protein A1 and A2 are essential components of the pulmonary surfactant system. SFTPA1 and SFTPA2 are glycoproteins with a molecular mass of approximately 26 kDa. These proteins are mainly expressed in the lung alveolar type II epithelial cells. They play a critical role in reducing surface tension in the alveoli preventing lung collapse during respiration. SFTPA1 and SFTPA2 bind to lipids within the surfactant helping to maintain its structure and function.
Biological function summary
SFTPA1 and SFTPA2 are involved in the immune defense mechanisms of the lungs. Both proteins are part of the collectin family and form higher-order oligomeric structures. As a component of the surfactant protein complex they enhance phagocytosis of pathogens by alveolar macrophages and neutralize pathogens directly. Additionally they modulate inflammatory responses in the lung therefore contributing to the protection of pulmonary tissues.
Pathways
SFTPA1 and SFTPA2 are integral to the innate immune response and lipid metabolism pathways in the lungs. They interact with toll-like receptors (TLRs) and other surfactant proteins like surfactant protein D (SFTPD) to activate signaling pathways that lead to inflammation control. SFTPA1 and SFTPA2 also influence surfactant homeostasis within the lung environment contributing to the maintenance of respiratory function.
SFTPA1 and SFTPA2 relate closely to respiratory distress syndrome (RDS) and pulmonary alveolar proteinosis (PAP). Mutations in SFTPA1 and SFTPA2 genes can impair surfactant function which often results in RDS particularly in premature infants. Moreover alterations in these proteins can also contribute to PAP where abnormal surfactant accumulation occurs. Their interplay with proteins like surfactant protein B (SFTPB) further links them to these pulmonary disorders as these proteins work together to ensure proper surfactant functionality.